BIOGEN INC. - COMMON S

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

01 Mar 2024 09:47:17 By NetDania Notify

Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMP

23 Feb 2024 07:00:26 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

20 Feb 2024 09:45:15 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

16 Feb 2024 09:48:44 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

15 Feb 2024 10:49:57 By NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

14 Feb 2024 12:24:11 By NetDania Notify

Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia

12 Feb 2024 16:06:00 By Nasdaq GlobeNewswire

Biogen to Realign Resources for Alzheimer's Disease Franchise

31 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission

19 Dec 2023 07:30:21 By Nasdaq GlobeNewswire

CHMP Issues Positive Opinion for Biogen’s SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia, a Rare Neurodegenerative Disease

15 Dec 2023 09:05:25 By Nasdaq GlobeNewswire

ZURZUVAE™ (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S.

14 Dec 2023 06:30:00 By Nasdaq GlobeNewswire

Biogen Appoints Monish Patolawala to its Board of Directors

06 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimer’s Disease (CTAD) Conference

25 Oct 2023 17:26:00 By Nasdaq GlobeNewswire

New Data from Biogen’s Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimer’s Disease

25 Oct 2023 10:51:00 By Nasdaq GlobeNewswire

Biogen to Present New Data at the Clinical Trials on Alzheimer’s Disease (CTAD) 2023 Meeting

19 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

FDA Approves Biogen’s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

29 Sep 2023 16:06:00 By Nasdaq GlobeNewswire

Biogen Completes Acquisition of Reata Pharmaceuticals

26 Sep 2023 08:59:54 By Nasdaq GlobeNewswire

LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’s Disease in Japan

25 Sep 2023 01:02:57 By Nasdaq GlobeNewswire

Biogen Appoints Jane Grogan as Head of Research

06 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral Treatment Approved for Women with Postpartum Depression, and Issues a Complete Response Letter for Major Depressive Disorder

04 Aug 2023 22:41:32 By Nasdaq GlobeNewswire